Related Experiment Video
Updated: Jul 14, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Appetite and obesity: a gastroenterologist's perspective
1Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER) Group, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. camilleri.michael@mayo.edu
Neurogastroenterology and Motility
|May 19, 2007
Summary
This review explores how the gastrointestinal tract regulates appetite and obesity treatments targeting the gut. It highlights gut hormones, stomach function, and therapeutic strategies for effective obesity management.
Area of Science:
- Gastroenterology and Endocrinology
Background:
- Obesity is a growing global health concern.
- The gastrointestinal (GI) tract plays a crucial role in appetite regulation and energy homeostasis.
- Understanding GI mechanisms is vital for developing effective obesity treatments.
Purpose of the Study:
- To review the role of the GI tract in appetite control.
- To examine gut-directed interventions for obesity treatment.
- To inform gastroenterologists about managing obese patients and GI treatment effects.
Main Methods:
- Literature review of studies on gut hormones, appetite, and GI motility.
- Analysis of evidence linking altered stomach function to satiation in obesity.
- Overview of current GI-tract-focused obesity therapies (pharmacological, device, endoscopic, surgical).
Main Results:
- Gut hormones significantly influence appetite and upper GI motility.
- Altered stomach function contributes to satiation in obese individuals.
- GI-targeted therapies include methods to impair fat absorption or modify stomach functions.
Conclusions:
- The GI tract is a key target for obesity interventions.
- Gastroenterologists must understand GI appetite regulation to manage obesity effectively.
- Awareness of treatment-induced GI alterations and complications is essential for patient care.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:30Regulation of Food Intake
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
01:20Taste Buds and Receptors
Gustation, or the sense of taste, is intrinsically linked to the anatomical structures located on the tongue. This organ's surface, along with the entirety of the oral cavity, is adorned with stratified squamous epithelium. Evident on the tongue are elevated structures known as papillae (singular = papilla), which house the mechanisms for the transduction of gustatory stimuli. Four distinct types of papillae exist, each identified by their unique morphological attributes: the circumvallate,...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...